Search
Edoxudine
go.drugbank.com/drugs/DB13421ApprovedWithdrawnIt was later recognized to be effective in vivo in a preclinical model of keratitis caused by herpes virus. … [A32643] It was developed by McNeil Pharmaceutical and approved by Health Canada on December 31, 1992. This medication was later discontinued from the market in 1998.[L1113]
Cerivastatin
go.drugbank.com/drugs/DB00439ApprovedWithdrawnOn August 8, 2001 the U.S. … It has also been withdrawn from the Canadian market.[A669,L43942]
Categories: Hypolipidemic Agents Indicated for HyperlipidemiaInsulin beef
go.drugbank.com/drugs/DB09456ApprovedInsulin beef has been discontinued in the US and Canada since 2017.[L10827]
Categories: Drugs Used in Diabetes, Insulins and Analogues for Injection, Fast-ActingVimseltinib
go.drugbank.com/drugs/DB17520ApprovedInvestigational[L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate … [L52230] It is highly selective, with a >500-fold selectivity for CSF1R over its nearest off-target kinase.
Solifenacin
go.drugbank.com/drugs/DB01591ApprovedInvestigational[L7511] It has a long duration of action as it is usually taken once daily.[L7511] Solifenacin was granted FDA approval on 19 November 2004.[L7511] … Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.
Categories: Drugs Used in Benign Prostatic Hypertrophy, Drugs for Urinary Frequency and IncontinencePenbutolol
go.drugbank.com/drugs/DB01359ApprovedInvestigationalWithdrawnThis binding characteristic of penbutolol is being investigated for its implications in Antidepressant Therapy. … Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker.
Categories: Beta Blocking Agents, Non-SelectiveLapatinib
go.drugbank.com/drugs/DB01259ApprovedInvestigationalIt was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. … Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer.
Synonyms: N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamineThrombin alfa
go.drugbank.com/drugs/DB11572ApprovedThe cell culture process used in the manufacture of Thrombin Alfa employs no additives of human or animal origin. … Thrombin Alfa precursor is secreted to culture medium as single chain form that is proteolytically converted to a two-chain active form (using a protein derived from snakes) and is purified by a chromatographic
Ixazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigational[A7948] More than 99% of the drug compound is the R-enantiomer.[A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US. … [A264319] It was later approved by Health Canada on August 3, 2016,[L51239] and by the EMA on November 21, 2016.
Nesiritide
go.drugbank.com/drugs/DB04899ApprovedInvestigationalWithdrawnNesiritide is a medication used to treat acutely decompensated congestive heart failure with dyspnea at rest or with minimal exertion (such as talk, eating or bathing). … Nesiritide is a 32 amino acid recombinant human B-type natriuretic peptide.
Categories: Vasodilators Used in Cardiac Diseases